# The Intersection of Heart Failure and Chronic Kidney Disease: Challenges in Co-management

## TL;DR

Heart failure and chronic kidney disease often occur together, complicating diagnosis and treatment, and this review explores the challenges and recent advances in managing these overlapping conditions.

## Contribution

This paper reviews the bidirectional relationship between heart failure and chronic kidney disease, emphasizing challenges in diagnosis, treatment limitations, and emerging therapeutic approaches.

## Key findings

- Heart failure and chronic kidney disease have a bidirectional relationship, leading to worsened outcomes.
- Current guideline-directed therapies for heart failure have limited use in advanced chronic kidney disease due to safety concerns.
- Emerging treatments like finerenone and SGLT-2 inhibitors show promise but require further study in advanced CKD and dialysis patients.

## Abstract

Heart failure (HF) and chronic kidney disease (CKD) frequently coexist, creating a bidirectional relationship where dysfunction of one organ accelerates deterioration of the other. This overlap is associated with high morbidity, mortality, and healthcare costs. Yet, patients with advanced CKD are systematically underrepresented in pivotal HF trials, resulting in major evidence gaps and therapeutic uncertainty. The pathophysiological interplay involves hemodynamic congestion, activation of the renin-angiotensin-aldosterone system (RAAS) and sympathetic nervous system (SNS), oxidative stress, inflammation, and nontraditional mediators such as uremic toxins and gut-derived metabolites, including trimethylamine-N-oxide (TMAO). Diagnosing HF in the context of CKD is challenging due to overlapping clinical features, limitations of biomarkers such as B-type natriuretic peptide (BNP) and N-terminal pro-B-type natriuretic peptide (NT-proBNP), and imaging constraints. At the same time, treatment is complicated by risks such as hyperkalemia, worsening renal function, and altered drug pharmacokinetics. Although guideline-directed medical therapies, including RAAS inhibitors, beta-adrenergic receptor blockers (beta-blockers), mineralocorticoid receptor antagonists (MRAs), and sodium-glucose cotransporter-2 (SGLT-2) inhibitors improve outcomes in HF, their use in advanced CKD is limited by safety concerns and lack of trial data. Recent advances include the nonsteroidal MRA finerenone and SGLT-2 inhibitors, which have demonstrated cardiovascular and renal benefits in patients with mild to moderate CKD, as well as acetazolamide, which has shown short-term efficacy as an adjunctive decongestive therapy in acute HF. However, the safety, efficacy, and clinical relevance of these approaches remain insufficiently defined in advanced CKD and in patients receiving dialysis. Multidisciplinary care models, precision medicine approaches, and digital innovations such as telemedicine and artificial intelligence-driven risk prediction promise to overcome fragmented management and improve patient-centered outcomes. This review highlights current challenges, synthesizes emerging evidence, and outlines future directions for optimizing the co-management of this complex and high-risk population.